Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,274 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06189391RecruitingPhase 1
Testing CN201 for people with relapsed or refractory B-cell lymphoma
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06185751RecruitingPhase 1
Testing CS1 CAR-T for multiple myeloma
This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.
St Louis, MissouriAges 18 years+ - NCT06177067RecruitingPhase 1
Study of 3 drugs for young AML patients with genetic changes
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
San Diego, CaliforniaAges 1–30 - NCT06132503RecruitingPhase 1
Testing LP-284 for advanced lymphomas and solid tumors
This trial tests an experimental drug called LP-284 in people with certain advanced lymphomas or solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against these cancers.
West Valley City, UtahAges 18 years+ - NCT06146257RecruitingPhase 1
Study of GLB-001 for Relapsed or Refractory AML or High-Risk MDS
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
Duarte, CaliforniaAges 18 years+ - NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06105554RecruitingPhase 1/Phase 2
Study of belumosudil for relapsed or refractory multiple myeloma
This trial tests a new drug called belumosudil, alone or with dexamethasone, for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if it can help when other therapies have stopped working.
Houston, TexasAges 18 years+ - NCT06017258RecruitingPhase 1
CAR T cell therapy for acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
Basking Ridge, New JerseyAges 1 year+ - NCT05370430RecruitingPhase 1
CAR T therapy targeting BAFF-R for certain NHL
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT05852717RecruitingPhase 2
Epcoritamab plus GDP chemotherapy for relapsed large B-cell lymphoma
This Phase 2 study tests epcoritamab combined with GDP chemotherapy to treat adults whose large B-cell lymphoma has come back or did not respond to prior treatment. It aims to improve how safely and effectively the disease can be controlled after standard chemotherapy.
Indianapolis, IndianaAges 18 years+ - NCT05833724RecruitingPhase 2
Chidamide for relapsed or resistant peripheral T-cell lymphoma
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Kaohsiung CityAges 20–75 - NCT05768529RecruitingPhase 1/Phase 2
U16 cell therapy for relapsed or refractory B-cell lymphoma
This trial tests a new cell therapy called U16 for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The therapy uses your own immune cells to target and attack the cancer cells.
Changsha, HunanAges 18–70 - NCT05650749Enrolling by invitationPhase 1
GPC2 car T cells for neuroblastoma and retinoblastoma
This trial tests a new treatment using engineered immune cells (CAR T cells) that target a protein called GPC2 found on some cancer cells. It is for patients with high-risk neuroblastoma or metastatic retinoblastoma that has returned or not responded to other treatments.
Philadelphia, PennsylvaniaAges 1 year+ - NCT05634369RecruitingPhase 1/Phase 2
NK cell and chemotherapy trial for relapsed soft tissue sarcoma
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
South Birmingham, AlabamaAges 2–40 - NCT05556642Recruiting
Liver tumor registry for children with relapsed cancer
This study collects information and may collect fresh tumor tissue to better understand and model relapsed or hard-to-treat liver tumors. Joining could help researchers develop future treatments and more personalized research for affected patients.
Cincinnati, OhioAges Any age - NCT05366218RecruitingPhase 1/Phase 2
Tafasitamab for kids with high-risk B-cell leukemia after relapse
This Phase 1/2 study tests tafasitamab in children and teens with B-lineage acute lymphoblastic leukemia (ALL) that has come back or did not respond. It is mainly for patients with specific high-risk leukemia changes and/or leukemia markers that stay after stem cell transplant or CAR T-cell therapy.
Freiburg im Breisgau, Baden-WurttembergAges 3–18 - NCT05344469Recruiting
Testing new MS medicines in people with active relapsing MS
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
Albstadt, Baden-WurttembergAges 18–100 - NCT05344833RecruitingPhase 2
Isatuximab and lenalidomide after transplant for myeloma
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
Chicago, IllinoisAges 18 years+ - NCT05105152RecruitingPhase 1
CAR T cell therapy for kids with CD33 AML that came back
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
Seattle, WashingtonAges Up to 30 years - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
La Jolla, CaliforniaAges 18 years+ - NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT04989803RecruitingPhase 1/Phase 2
Tested two lymphoma cell therapies for relapsed or resistant cancer
This trial studies two investigational cell therapies (KITE-363 or KITE-753) in people whose B-cell lymphoma has returned or did not respond to prior treatment. The goal is to see how safe the treatments are and how well they can shrink the lymphoma.
Gilbert, ArizonaAges 18 years+ - NCT04989621RecruitingPhase 2
Orelabrutinib plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
Guangzhou, GuangdongAges 18 years+ - NCT04661137RecruitingPhase 2
Combination treatment for multiple myeloma that has stopped responding
This study tests a new combination of drugs for people with multiple myeloma that has stopped responding to previous treatments. The goal is to see if adding selinexor to other anti-myeloma drugs can help control the disease.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,274 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.